We aimed to develop a method for estimating inpatient costs for pediatric patients with acute myeloid leukemia ( AML ) enrolled on NCI-funded Phase III trials , compare costs between AAML0531 treatment arms ( standard chemotherapy gemtuzumab ozogamicin ( GMTZ ) ) , and evaluate primary drivers of costs for newly diagnosed pediatric AML .